Latest Manufacturing And Distribution News

Page 4 of 10
Radiopharm Theranostics has secured a clinical supply agreement with Siemens Healthineers to manufacture and distribute RAD101, advancing its Phase 3 trial in the U.S. Interim Phase 2b data showed 90% concordance with MRI in detecting brain metastases.
Ada Torres
Ada Torres
7 Apr 2026
Nexsen Limited (ASX:NXN) has completed its Stage 1 ISO 13485 audit, confirming its Quality Management System (QMS) supports clinical validation and regulatory submissions for its diagnostic products, including StrepSure®. The company is progressing toward full certification and alignment with MDSAP requirements to facilitate global market access.
Ada Torres
Ada Torres
7 Apr 2026
Nexsen Limited's subsidiary has won a HK$6 million grant to accelerate clinical validation and manufacturing of its rapid Group B Streptococcus diagnostic in Hong Kong, positioning the city as a key Asia-Pacific hub.
Ada Torres
Ada Torres
31 Mar 2026
DGL Group Limited has replaced its ANZ-led financing with a new $120 million facility from ScotPac, extending maturity and enhancing working capital flexibility amid ongoing management restructuring.
Victor Sage
Victor Sage
27 Mar 2026
EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.
Ada Torres
Ada Torres
10 Mar 2026
Pure Foods Tasmania reports a significant operational turnaround in 1H FY26, driven by strategic cost reductions, expanded distribution deals with major retailers, and the acquisition of premium ice cream brand Elato.
Victor Sage
Victor Sage
4 Mar 2026
Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.
Victor Sage
Victor Sage
26 Feb 2026
Star Combo Pharma reported a 23% decline in revenue to $11.9 million for the half year ended December 2025, driven by the loss of a major OEM contract and closure of its AustoYou retail business. Despite this, operating profit after tax rose 49% to $413,243, reflecting effective cost management.
Ada Torres
Ada Torres
25 Feb 2026
Sea Forest Limited has reported a remarkable 236% increase in SeaFeed revenue for the first half of 2026, surpassing breakeven cattle commitments and securing new international partnerships.
Ada Torres
Ada Torres
25 Feb 2026
Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.
Ada Torres
Ada Torres
20 Feb 2026
Fletcher Building reports a stable half-year performance despite subdued markets, advancing its strategic pivot with the announced sale of its Construction division.
Victor Sage
Victor Sage
18 Feb 2026
Centuria Industrial REIT has released its HY26 Property Compendium, detailing a diversified portfolio of industrial assets across Australia valued at nearly $4 billion. The report highlights strong occupancy, long lease terms, and strategic locations near major infrastructure.
Eva Park
Eva Park
11 Feb 2026

Browse the archive

Full archive